On Day 3 of MIPIM 2026 in Cannes, Woodbourne Group unveiled Birmingham BioCity, a 130,000ft2, £90m ($120m) purpose-built life sciences facility in the heart of Birmingham’s Knowledge Quarter. The launch marks the first Investment Zone life sciences building outside London, signalling a shift in the UK’s innovation landscape as regional hubs rise to meet growing demand.
Designed to accommodate small, IP-rich firms often priced out of London and Cambridge, the canal-side development offers fitted Containment Level 2 (CL2) laboratories, flexible office spaces, and collaboration hubs. With a planned eight-minute walk to HS2 Curzon Street station, Birmingham BioCity promises rapid connectivity to London, reducing journey times to just 42 minutes once services commence.
Meeting the UK life sciences lab space shortage
The UK life sciences sector, valued at an estimated £100bn ($134bn) and supporting approximately 400,000 jobs, faces a structural undersupply of high-specification lab space. Prime rents in London and Cambridge now sit at £140 and £80 per square foot, respectively, leaving many start-ups and scaling firms searching for affordable, high-quality facilities. Birmingham BioCity aims to fill this gap, offering a government-backed Investment Zone with tax incentives, reduced business rates, and access to strategic support programmes.
Highlighting the project’s strategic relevance, Tani Dulay, CEO of Woodbourne Group, said, “Birmingham BioCity connects regional talent and research to London’s Golden Triangle, delivering institutional-grade laboratory infrastructure at a scale and cost those markets increasingly cannot match.”
Birmingham Knowledge Quarter: Driving life sciences growth
Birmingham BioCity is Phase 1 of a 600,000ft2 life sciences pipeline, projected to unlock £210m in investment. The broader Knowledge Quarter programme, a £4bn innovation district, aims to create about 48,000 jobs and generate £3bn in gross value added (GVA). Sustainability has been prioritised, with the facility targeting BREEAM Outstanding, WiredScore Platinum, and EPC ‘A’ ratings, and a 60/40 lab-to-office split to encourage collaboration and commercial growth.
Birmingham BioCity: Connecting innovation and life sciences investment
The project is strengthened by Woodbourne Group’s £400m partnership with global investor Hines, highlighting the growing trend of cross-sector collaboration to attract investment outside traditional life sciences hubs. Charlie Nunn, Group CEO of Lloyds Banking Group, praised Birmingham BioCity as “a platform for future growth and high-skilled job creation,” underscoring financial sector confidence in the region.
With government backing and modern facilities, Birmingham BioCity represents a step towards the decentralisation of the UK’s life sciences sector, creating space for regional innovation and investment.
